Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get in-depth healthcare industry analysis with the unparalleled resources at Informa Pharma Intelligence.
Download your copy of this essential whitepaper, which provides a window into the rapidly evolving world of personalized medicine, and the accompanying outlook for related clinical trials.
One Size No Longer Fits All: The Personalized Medicine Trial Landscape includes:
HBW Insight
14 Feb 2019
France's self-medication market had a difficult 2018, due to a weak flu season and changing dynamics in the sector, according to industry association Afipa. Despite this it was a good year for Sanofi, which overtook Boiron as the number-one OTC firm in the market, while its Doliprane analgesic became France's best-selling brand.
Topic Drug review
Generics Bulletin
14 Feb 2019
Alvogen is claiming the first European launch of a generic rival to Revlimid, rolling out the oncology drug in several central and eastern European markets. Meanwhile, IPR challenges to three Revlimid patents in the US have been denied.
Topic Drug review
Pink Sheet
By Michael McCaughan 14 Feb 2019
Here is what to expect from – and some free advice for – seven industry executives as they prepare for a hearing on drug pricing in the Senate Finance Committee.
Topic Drug approval
Medtech Insight
By Ferdous Al-Faruque 14 Feb 2019
Despite a recent report that Sen. Amy Klobuchar, D-Minn., is backing away from leading efforts to repeal the medical device tax due to her presidential ambitions, sources say she is working with Sen. Pat Toomey, R-Pa., to cosponsor a repeal bill this year. Similarly, on the US House-side, Rep. Ron Kind, D-Wisc., is calling on his colleagues to support a full repeal bill as well.
Topic Medtech
Medtech Insight
By Ashley Yeo 14 Feb 2019
The EU Medical Device Regulation is 15 months away from being implemented in full, and a new German survey about its potential impact on the medtech innovation and patient-care landscape makes for sobering reading.
Topic Medtech
Scrip
By Joseph Haas 14 Feb 2019
Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend of disappointments outside of its antiviral franchises. Analysts don’t expect the second Phase III study in less-sick patients to succeed either.
Topic Drug review Drug approval Drug development landscape Clinical trials
Scrip
By John Davis 14 Feb 2019
Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.
Topic Cancer
Pink Sheet
By Brenda Sandburg 07 Feb 2019
'Number of different initiatives' coming in next several months to make drugs more affordable, including for PrEP prophylaxis, HHS Assistant Secretary for Health Giroir says. Multi-agency approach is key strategy.
Medtech Insight
By Amanda Maxwell 07 Feb 2019
With a growing urgency for medtech manufacturers to take decisive action so their products are not banned from the market under an increasingly likely no-deal Brexit, clients of BSI will be relieved to hear their notified body believes time is on their side.
Topic Medtech
Medtech Insight
By Elizabeth Orr 07 Feb 2019
The US Department of Homeland Security National Cybersecurity and Communications Integration Center is warning of potential cybersecurity vulnerabilities in Stryker hospital beds and BD diagnostics equipment.
Scrip
07 Feb 2019
The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.
Topic Business strategies Drug approval Drug development landscape Drug review
Scrip
By Alexandra Shimmings 07 Feb 2019
Novartis may be turning up the rhetoric in spinal muscular atrophy as its cutting-edge gene therapy Zolgensma approaches a market currently enjoyed solely by Biogen’s Spinraza, but Roche is upbeat about the potential of its investigational oral product, risdiplam, to weigh in.
Topic Business strategies Drug approval Drug development landscape
Primal Pictures
04 Feb 2019
This whitepaper explores how best in class anatomy, physiology and clinical content, images and customized solutions enable organizations to achieve strong competitive advantage, drive credibility, productivity and differentiation. We will share ideas that you can consistently apply to your own organization to reach business and revenue goals. Finally, we will conclude with a checklist of what to look for when selecting your anatomy content solution.
Citeline
By Heidi Chen 01 Feb 2019
Twenty years ago, there was a shift in pain management, and it became more common to prescribe opioids for chronic pain.
Topic Drug review
Citeline
01 Feb 2019
With opioid abuse and deaths in the US at an all-time high, the journey to battle the opioid epidemic continues – keeping drug companies and the FDA working hard to come up with effective alternatives for pain.
Topic Drug approval Drug review
Medtech Insight
18 Feb 2019
Scrip
18 Feb 2019
Scrip
17 Feb 2019
Medtech Insight
15 Feb 2019
Scrip
15 Feb 2019
Scrip
15 Feb 2019
Pink Sheet
15 Feb 2019
Medtech Insight
15 Feb 2019
Pink Sheet
15 Feb 2019
Medtech Insight
15 Feb 2019
Pink Sheet
15 Feb 2019
Medtech Insight
15 Feb 2019
Scrip
15 Feb 2019
Pink Sheet
15 Feb 2019
Medtech Insight
15 Feb 2019
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
